Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
Year: 2017
Type: article
Abstract: This document provides clinical recommendations for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations. It represents a collaborative effort between the European Respiratory Society and the American Thoracic Society. Comprehensive evidence syntheses were performed to summarise all available evidence relevant to the Task Force's questions. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach and the results were summarised in evidence profiles. The evidence syntheses were discussed and recommendations formulated by a multidisciplinary Task Force of COPD experts. After considering the balance of desirable (benefits) and undesirable consequences (burden in the form of adverse effects and cost), quality of evidence, feasibility, and acceptability of various interventions, the Task Force made recommendations for mucolytic, long-acting muscarinic antagonist, phosphodiesterase-4 inhibitor (roflumilast) and macrolide therapy, as well as a conditional recommendation against fluoroquinolone therapy. All of the recommendations were conditional, except for a strong recommendation for the use of a long-acting antimuscarinic agentversusa long-acting β2-adrenergic, indicating that there was uncertainty about the balance of desirable and undesirable consequences of the intervention, and that well-informed patients may make different choices regarding whether to have or not have the specific intervention. The guideline summarises the evidence and provides recommendations for pharmacological therapy for the prevention of COPD exacerbations.
Source: European Respiratory Journal
Authors: Jadwiga A. Wedzicha, Peter M.A. Calverley, Richard K. Albert, Antonio Anzueto, Gerard J. Criner, John R. Hurst, Marc Miravitlles, Alberto Papi, Klaus F. Rabe, David Rigau, Pawel Sliwinski, Thomy Tonia, Jørgen Vestbo, Kevin C. Wilson, Jerry A. Krishnan
Institutions: Imperial College London, University of Liverpool, University of Colorado Denver, The University of Texas at San Antonio Health Science Center, South Texas Veterans Health Care System, Temple University, University College London, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Vall d'Hebron Hospital Universitari, University of Ferrara, Christian-Albrechts-Universität zu Kiel, German Center for Lung Research, LungenClinic Grosshansdorf, Iberoamerican Cochrane Centre, University of Bern, University of Manchester, Boston University, University of Illinois Hospital & Health Sciences System
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: chronic obstructive pulmonary disease, COPD exacerbations, exacerbation prevention, mucolytic therapy, long-acting muscarinic antagonist, phosphodiesterase-4 inhibitors, roflumilast, macrolide therapy, fluoroquinolone therapy, long-acting beta2-agonists, antimuscarinic agents, pharmacotherapy
Open Access status: bronze
OpenAlex ID: W4256679850
